The efficacy and safety of ramucirumab plus docetaxel in older patients with advanced non-small cell lung cancer.
Adenocarcinoma of Lung
/ drug therapy
Adult
Aged
Aged, 80 and over
Antibodies, Monoclonal, Humanized
/ administration & dosage
Antineoplastic Combined Chemotherapy Protocols
/ adverse effects
Carcinoma, Non-Small-Cell Lung
/ drug therapy
Carcinoma, Squamous Cell
/ drug therapy
Docetaxel
/ administration & dosage
Female
Follow-Up Studies
Humans
Lung Neoplasms
/ drug therapy
Male
Middle Aged
Neoplasm Staging
Patient Safety
Prognosis
Retrospective Studies
Survival Rate
Ramucirumab
Docetaxel
PEG-G-CSF
non-small cell lung cancer
older patients
ramucirumab
Journal
Thoracic cancer
ISSN: 1759-7714
Titre abrégé: Thorac Cancer
Pays: Singapore
ID NLM: 101531441
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
received:
31
01
2020
revised:
20
03
2020
accepted:
21
03
2020
pubmed:
16
4
2020
medline:
16
3
2021
entrez:
16
4
2020
Statut:
ppublish
Résumé
Ramucirumab plus docetaxel (RAM+DOC) is expected to prolong survival in patients with advanced non-small cell lung cancer (NSCLC); however, the efficacy and safety for older patients remains unknown. The objective of this study was to evaluate the efficacy and safety of RAM+DOC in patients 75 years and older. We retrospectively reviewed consecutive patients with advanced NSCLC who had received RAM+DOC treatment at three institutions. We compared the efficacy and safety in patients 75 years and older to those under 75 years of age. A total of 114 patients were identified. The median progression-free survival, time to treatment failure and overall survival was 3.6 (95% CI: 0.4-6.7), 3.1 (95% CI: 2.4-3.9) and 11.2 months (95% CI: 5.6-16.8) in the older group (N = 23), and 4.2 (95% CI: 3.3-5.0), 3.4 (95% CI: 3.3-5.0) and 12.2 months (95% CI: 9.1-15.4) in the younger group (N = 91), respectively. Survival curves were similar for each group, while the objective response rate was 30.4% (95% CI: 13.2-52.9%) in older patients and 35.2% (95% CI, 25.4-45.9%) for the younger group. A total of 22 older patients (95.7%) and 73 (80.2%) younger patients received primary prophylactic pegylated-granulocyte-colony stimulating factor (PEG-G-CSF). Four older patients (17.3%) and 14 younger patients (15.3%) discontinued RAM+DOC due to adverse events. RAM+DOC is expected to be efficacious and tolerable in older patients when supported with prophylactic PEG-G-CSF therapy. Significant findings of the study ・PFS, OS, and ORR in older patients were similar to those under 75 years of age. ・Safety of RAM+DOC was well tolerated in older patients with prophylactic PEG-G-CSF. ・Prophylactic PEG-G-CSF with RAM+DOC may contribute to better efficacy. What this study adds ・This study suggests that RAM+DOC with prophylactic PEG-G-CSF is expected to be a useful option in older patients with advanced NSCLC.
Sections du résumé
BACKGROUND
Ramucirumab plus docetaxel (RAM+DOC) is expected to prolong survival in patients with advanced non-small cell lung cancer (NSCLC); however, the efficacy and safety for older patients remains unknown. The objective of this study was to evaluate the efficacy and safety of RAM+DOC in patients 75 years and older.
METHODS
We retrospectively reviewed consecutive patients with advanced NSCLC who had received RAM+DOC treatment at three institutions. We compared the efficacy and safety in patients 75 years and older to those under 75 years of age.
RESULTS
A total of 114 patients were identified. The median progression-free survival, time to treatment failure and overall survival was 3.6 (95% CI: 0.4-6.7), 3.1 (95% CI: 2.4-3.9) and 11.2 months (95% CI: 5.6-16.8) in the older group (N = 23), and 4.2 (95% CI: 3.3-5.0), 3.4 (95% CI: 3.3-5.0) and 12.2 months (95% CI: 9.1-15.4) in the younger group (N = 91), respectively. Survival curves were similar for each group, while the objective response rate was 30.4% (95% CI: 13.2-52.9%) in older patients and 35.2% (95% CI, 25.4-45.9%) for the younger group. A total of 22 older patients (95.7%) and 73 (80.2%) younger patients received primary prophylactic pegylated-granulocyte-colony stimulating factor (PEG-G-CSF). Four older patients (17.3%) and 14 younger patients (15.3%) discontinued RAM+DOC due to adverse events.
CONCLUSIONS
RAM+DOC is expected to be efficacious and tolerable in older patients when supported with prophylactic PEG-G-CSF therapy.
KEY POINTS
Significant findings of the study ・PFS, OS, and ORR in older patients were similar to those under 75 years of age. ・Safety of RAM+DOC was well tolerated in older patients with prophylactic PEG-G-CSF. ・Prophylactic PEG-G-CSF with RAM+DOC may contribute to better efficacy. What this study adds ・This study suggests that RAM+DOC with prophylactic PEG-G-CSF is expected to be a useful option in older patients with advanced NSCLC.
Identifiants
pubmed: 32291896
doi: 10.1111/1759-7714.13429
pmc: PMC7262941
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Docetaxel
15H5577CQD
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1559-1565Informations de copyright
© 2020 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.
Références
J Clin Oncol. 2010 Feb 10;28(5):780-7
pubmed: 20048182
Lung Cancer. 2019 Sep;135:188-195
pubmed: 31446994
J Clin Oncol. 2015 Feb 20;33(6):575-81
pubmed: 25584004
Thorac Cancer. 2019 Apr;10(4):1005-1008
pubmed: 30859745
BMC Cancer. 2011 Sep 23;11:404
pubmed: 21943360
Lancet. 2011 Sep 17;378(9796):1079-88
pubmed: 21831418
Lancet. 2014 Aug 23;384(9944):665-73
pubmed: 24933332
Ann Oncol. 2013 Feb;24(2):314-21
pubmed: 23123509
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Clin Lung Cancer. 2018 May;19(3):270-279.e3
pubmed: 29373274
Clin Lung Cancer. 2018 Nov;19(6):e865-e869
pubmed: 30206044
Respir Investig. 2019 Jan;57(1):27-33
pubmed: 30293944
Oncotarget. 2018 Jun 12;9(45):27789-27796
pubmed: 29963237
Lung Cancer. 2016 Sep;99:186-93
pubmed: 27565938
J Clin Oncol. 2006 Aug 1;24(22):3657-63
pubmed: 16877734
Lancet. 2015 May 9;385(9980):1863-72
pubmed: 25740286